経口医薬製剤の世界市場

◆英語タイトル:Oral Solid Dosage Pharmaceutical Formulation Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027
◆商品コード:FUMI709067
◆発行会社(調査会社):Future Market Insights
◆発行日:2017年7月18日
◆ページ数:195
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Individual PriceUSD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Corporate PriceUSD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規販売代理店です。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。
Future Market Insightsが発行した本調査レポートでは、経口医薬製剤の世界市場について調査・分析し、経口医薬製剤の世界市場動向、経口医薬製剤の世界市場規模、市場予測、セグメント別経口医薬製剤市場分析、地域別市場規模(北米市場、南米市場、アジア市場、日本市場、ヨーロッパ市場など)、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from US$ 493.2 Bn in 2017 to US$ 926.3 Bn by 2027 end. This represents a value CAGR of 6.5% over the forecast period 2017– 2027. Several important factors drive this growth. We present these factors in detail in our report. A snapshot is captured below for our readers’ benefit.
Growth Factor : Most promising yet cost-effective dosage form

Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well. For instance, oral solid dosage forms are often chosen by patients owing to the inherent advantages in dosage administration and no necessity of dose measurement. They can be formulated in different flavours and in different dosage forms in order to increase patient compliance. For instance, few APIs have unpleasant taste, and in order to avoid this, they are manufactured in the form of effervescent tablets to achieve patient acceptability and compliance. Recent advances in drug delivery are enabling oral solid dosage manufacturers to achieve significant bioavailability by adopting novel drug delivery technology platforms. For example, targeted drug delivery and sustained release of dosage forms in oral solid dosage formulations enhance the bioavailability of the drugs and reduce the frequent administration of drugs, thereby contributing to significant growth of oral solid dosage forms.

Growth Factor : Growth in APEJ region driven by rise in affluent consumers and super generics

Huge boost in the APEJ market for oral solid dosage pharmaceutical formulations is coming from a sharp rise in new affluent consumers in countries such as India, China and Korea. Both multinational companies as well as local drug manufacturers are benefiting from the rapidly growing population of India and China. This group of affluent consumers is adopting a wealthy and fast-paced western lifestyle and thus have begun to suffer with western lifestyle related diseases such as diabetes, cancer and obesity, for which they seek and can afford innovative drug treatments. Moreover, generic manufacturers have entered into the production of super-generics i.e., modified versions of approved off-patent small-molecule drugs that offer a therapeutic advantage and thus distinguish them from me-too generic drugs. For instance, Ranbaxy Laboratories Ltd. – India based manufacturer of generic medicine – has developed once-a day Ciprofloxacin tablet, a super generic antibiotic. The company licensed it to Bayer and opened up an opportunity in the global market.

Global Oral Solid Dosage Pharmaceutical Formulation Market Attractiveness Analysis, By Region

North America dominated the global oral solid dosage pharmaceutical formulation market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the most lucrative among all regions, with a market attractiveness index of 2.7. Consolidation of the pharmaceutical industry in the U.S. combined with an expansion in outsourcing is boosting revenue growth of the oral solid dosage pharmaceutical formulation market in the region. APEJ is expected to be the second most lucrative market for oral solid dosage pharmaceuticals, with a market attractiveness index of 2.6. APEJ remains the third largest market due to rapidly increasing penetration of generics in China and India. MEA is expected to remain the least attractive regional market in terms of revenue, with a market attractiveness index of 0.1 over the forecast period. Every market is challenged by certain factors that tend to hamper overall growth. We have focussed on these growth limiters in detail in our report. One such factor restraining market growth is highlighted below.

Diminishing share of oral solids in the development pipeline

Growing research on biologics molecules and their dominance in treating oncology conditions are hampering the growth of the oral solid dosage pharmaceutical formulation market. Furthermore, investments by government organisations to conduct research activities in biologics coupled with an increase in biotech start-ups have had a negative impact on oral solid dosage forms. According to an article published in Contract Pharma, approximately 50% of the pipeline molecules are biologics and the rest in the form of other dosage forms. Companies are betting heavily on biologics owing to their high returns in terms of value. For instance, in 2016, the top 10 drugs generated around US$ 79 Bn in terms of value; among these, 76.8% were from biologics.

【レポートの目次】

Table Of Content

1.Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2.Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3.Oral Solid Dosage Pharmaceuticals Market View Point

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

4.North America Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Regional Market Dynamics

4.2.1.Drivers

4.2.2.Restraints

4.2.3.Trends

4.3. Historical Market Size (US$ Mn) By Country, 2012-2016

4.3.1.U.S.

4.3.2.Canada

4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

4.4.1.U.S.

4.4.2.Canada

4.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

4.5.1.Tablets

4.5.2.Capsules

4.5.3.Powders

4.5.4.Others

4.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

4.6.1.Tablets

4.6.2.Capsules

4.6.3.Powders

4.6.4.Others

4.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

4.7.1.Immediate Release

4.7.2.Extended Release

4.7.2.1. Sustained Release

4.7.2.2. Controlled Release

4.7.3.Others

4.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

4.8.1.Immediate Release

4.8.2.Extended Release

4.8.2.1. Sustained Release

4.8.2.2. Controlled Release

4.8.3.Others

4.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

4.9.1.Hospital Pharmacy

4.9.2.Retail Pharmacy

4.9.3.Drug Stores

4.9.4.Online Pharmacy

4.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

4.10.1.Hospital Pharmacy

4.10.2.Retail Pharmacy

4.10.3.Drug Stores

4.10.4.Online Pharmacy

4.11. Drivers and Restraints: Impact Analysis

4.12. Market Attractiveness Analysis

4.12.1.By Country

4.12.2.By Dosage Form

4.12.3.By Drug Release Mechanism

4.12.4.By Distribution Channel

4.13. Key Representative Market Participants

4.14. Key Participants Market Presence (Intensity Map)

5.Western Europe Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Regional Market Dynamics

5.2.1.Drivers

5.2.2.Restraints

5.2.3.Trends

5.3. Historical Market Size (US$ Mn) By Country, 2012-2016

5.3.1.Germany

5.3.2.U.K

5.3.3.France

5.3.4.Italy

5.3.5.Spain

5.3.6.Rest of Western Europe

5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

5.4.1.Germany

5.4.2.U.K

5.4.3.France

5.4.4.Italy

5.4.5.Spain

5.4.6.Rest of Western Europe

5.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

5.5.1.Tablets

5.5.2.Capsules

5.5.3.Powders

5.5.4.Others

5.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

5.6.1.Tablets

5.6.2.Capsules

5.6.3.Powders

5.6.4.Others

5.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

5.7.1.Immediate Release

5.7.2.Extended Release

5.7.2.1. Sustained Release

5.7.2.2. Controlled Release

5.7.3.Others

5.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

5.8.1.Immediate Release

5.8.2.Extended Release

5.8.2.1. Sustained Release

5.8.2.2. Controlled Release

5.8.3.Others

5.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

5.9.1.Hospital Pharmacy

5.9.2.Retail Pharmacy

5.9.3.Drug Stores

5.9.4.Online Pharmacy

5.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

5.10.1.Hospital Pharmacy

5.10.2.Retail Pharmacy

5.10.3.Drug Stores

5.10.4.Online Pharmacy

5.11. Drivers and Restraints: Impact Analysis

5.12. Market Attractiveness Analysis

5.12.1.By Country

5.12.2.By Dosage Form

5.12.3.By Drug Release Mechanism

5.12.4.By Distribution Channel

5.13. Key Representative Market Participants

5.14. Key Participants Market Presence (Intensity Map)

6.Eastern Europe Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Regional Market Dynamics

6.2.1.Drivers

6.2.2.Restraints

6.2.3.Trends

6.3. Historical Market Size (US$ Mn) By Country, 2012-2016

6.3.1.Russia

6.3.2.Poland

6.3.3.Rest of Eastern Europe

6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

6.4.1.Russia

6.4.2.Poland

6.4.3.Rest of Eastern Europe

6.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

6.5.1.Tablets

6.5.2.Capsules

6.5.3.Powders

6.5.4.Others

6.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

6.6.1.Tablets

6.6.2.Capsules

6.6.3.Powders

6.6.4.Others

6.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

6.7.1.Immediate Release

6.7.2.Extended Release

6.7.2.1. Sustained Release

6.7.2.2. Controlled Release

6.7.3.Others

6.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

6.8.1.Immediate Release

6.8.2.Extended Release

6.8.2.1. Sustained Release

6.8.2.2. Controlled Release

6.8.3.Others

6.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

6.9.1.Hospital Pharmacy

6.9.2.Retail Pharmacy

6.9.3.Drug Stores

6.9.4.Online Pharmacy

6.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

6.10.1.Hospital Pharmacy

6.10.2.Retail Pharmacy

6.10.3.Drug Stores

6.10.4.Online Pharmacy

6.11. Drivers and Restraints: Impact Analysis

6.12. Market Attractiveness Analysis

6.12.1.By Country

6.12.2.By Dosage Form

6.12.3.By Drug Release Mechanism

6.12.4.By Distribution Channel

6.13. Key Representative Market Participants

6.14. Key Participants Market Presence (Intensity Map)

7.Latin America Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Regional Market Dynamics

7.2.1.Drivers

7.2.2.Restraints

7.2.3.Trends

7.3. Historical Market Size (US$ Mn) By Country, 2012-2016

7.3.1.Brazil

7.3.2.Mexico

7.3.3.Rest of Latin America

7.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

7.4.1.Brazil

7.4.2.Mexico

7.4.3.Rest of Latin America

7.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

7.5.1.Tablets

7.5.2.Capsules

7.5.3.Powders

7.5.4.Others

7.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

7.6.1.Tablets

7.6.2.Capsules

7.6.3.Powders

7.6.4.Others

7.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

7.7.1.Immediate Release

7.7.2.Extended Release

7.7.2.1. Sustained Release

7.7.2.2. Controlled Release

7.7.3.Others

7.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

7.8.1.Immediate Release

7.8.2.Extended Release

7.8.2.1. Sustained Release

7.8.2.2. Controlled Release

7.8.3.Others

7.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

7.9.1.Hospital Pharmacy

7.9.2.Retail Pharmacy

7.9.3.Drug Stores

7.9.4.Online Pharmacy

7.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

7.10.1.Hospital Pharmacy

7.10.2.Retail Pharmacy

7.10.3.Drug Stores

7.10.4.Online Pharmacy

7.11. Drivers and Restraints: Impact Analysis

7.12. Market Attractiveness Analysis

7.12.1.By Country

7.12.2.By Dosage Form

7.12.3.By Drug Release Mechanism

7.12.4.By Distribution Channel

7.13. Key Representative Market Participants

7.14. Key Participants Market Presence (Intensity Map)

8.Asia Pacific Excluding Japan Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Regional Market Dynamics

8.2.1.Drivers

8.2.2.Restraints

8.2.3.Trends

8.3. Historical Market Size (US$ Mn) By Country, 2012-2016

8.3.1.China

8.3.2.India

8.3.3.Australia and New Zealand

8.3.4.ASEAN

8.3.5.Rest of APEJ

8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

8.4.1.China

8.4.2.India

8.4.3.Australia and New Zealand

8.4.4.ASEAN

8.4.5.Rest of APEJ

8.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

8.5.1.Tablets

8.5.2.Capsules

8.5.3.Powders

8.5.4.Others

8.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

8.6.1.Tablets

8.6.2.Capsules

8.6.3.Powders

8.6.4.Others

8.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

8.7.1.Immediate Release

8.7.2.Extended Release

8.7.2.1. Sustained Release

8.7.2.2. Controlled Release

8.7.3.Others

8.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

8.8.1.Immediate Release

8.8.2.Extended Release

8.8.2.1. Sustained Release

8.8.2.2. Controlled Release

8.8.3.Others

8.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

8.9.1.Hospital Pharmacy

8.9.2.Retail Pharmacy

8.9.3.Drug Stores

8.9.4.Online Pharmacy

8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

8.10.1.Hospital Pharmacy

8.10.2.Retail Pharmacy

8.10.3.Drug Stores

8.10.4.Online Pharmacy

8.11. Drivers and Restraints: Impact Analysis

8.12. Market Attractiveness Analysis

8.12.1.By Country

8.12.2.By Dosage Form

8.12.3.By Drug Release Mechanism

8.12.4.By Distribution Channel

8.13. Key Representative Market Participants

8.14. Key Participants Market Presence (Intensity Map)

9.Japan Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Regional Market Dynamics

9.2.1.Drivers

9.2.2.Restraints

9.2.3.Trends

9.3. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

9.3.1.Tablets

9.3.2.Capsules

9.3.3.Powders

9.3.4.Others

9.4. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

9.4.1.Tablets

9.4.2.Capsules

9.4.3.Powders

9.4.4.Others

9.5. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

9.5.1.Immediate Release

9.5.2.Extended Release

9.5.2.1. Sustained Release

9.5.2.2. Controlled Release

9.5.3.Others

9.6. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

9.6.1.Immediate Release

9.6.2.Extended Release

9.6.2.1. Sustained Release

9.6.2.2. Controlled Release

9.6.3.Others

9.7. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

9.7.1.Hospital Pharmacy

9.7.2.Retail Pharmacy

9.7.3.Drug Stores

9.7.4.Online Pharmacy

9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

9.8.1.Hospital Pharmacy

9.8.2.Retail Pharmacy

9.8.3.Drug Stores

9.8.4.Online Pharmacy

9.9. Drivers and Restraints: Impact Analysis

9.10. Market Attractiveness Analysis

9.10.1.By Dosage Form

9.10.2.By Drug Release Mechanism

9.10.3.By Distribution Channel

9.11. Key Representative Market Participants

9.12. Key Participants Market Presence (Intensity Map)

10. Middle East and Africa Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

10.1. Introduction

10.2. Regional Market Dynamics

10.2.1.Drivers

10.2.2.Restraints

10.2.3.Trends

10.3. Historical Market Size (US$ Mn) By Country, 2012-2016

10.3.1.GCC Countries

10.3.2.South Africa

10.3.3.Rest of Middle East and Africa

10.4. Market Size (US$ Mn) Forecast By Country, 2017-2027

10.4.1.GCC Countries

10.4.2.South Africa

10.4.3.Rest of Middle East and Africa

10.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

10.5.1.Tablets

10.5.2.Capsules

10.5.3.Powders

10.5.4.Others

10.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

10.6.1.Tablets

10.6.2.Capsules

10.6.3.Powders

10.6.4.Others

10.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

10.7.1.Immediate Release

10.7.2.Extended Release

10.7.2.1.Sustained Release

10.7.2.2.Controlled Release

10.7.3.Others

10.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

10.8.1.Immediate Release

10.8.2.Extended Release

10.8.2.1.Sustained Release

10.8.2.2.Controlled Release

10.8.3.Others

10.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

10.9.1.Hospital Pharmacy

10.9.2.Retail Pharmacy

10.9.3.Drug Stores

10.9.4.Online Pharmacy

10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

10.10.1.Hospital Pharmacy

10.10.2.Retail Pharmacy

10.10.3.Drug Stores

10.10.4.Online Pharmacy

10.11. Drivers and Restraints: Impact Analysis

10.12. Market Attractiveness Analysis

10.12.1.By Country

10.12.2.By Dosage Form

10.12.3.By Drug Release Mechanism

10.12.4.By Distribution Channel

10.13. Key Representative Market Participants

10.14. Key Participants Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

13.1. Market Structure

13.2. Competition Intensity Mapping By Market Taxonomy

13.3. Competition Dashboard

13.4. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

13.4.1.AstraZeneca Plc.

13.4.2.Bristol-Myers Squibb Company

13.4.3.Eli Lilly and Company

13.4.4.Gilead Sciences

13.4.5.Merck & Co. Inc.

13.4.6.Novartis AG

13.4.7.Pfizer Inc.

13.4.8.AbbVie Inc.

13.4.9. Boehringer Ingelheim GmbH

13.4.10.Hoffman-La-Roche Ltd.

13.4.11. Johnson & Johnson

13.4.12. Biogen Inc.

13.4..13. Bayer AG

13.5.14. Teva Pharmaceticals

13.5.15. Amgen Inc.

13.5.16. Takeda Pharmaceutical Company Ltd.

13.5.17. Otsuka Pharmaceutical Co., Ltd.

13.5.18. Shire Plc.

13.5.19. Celgene Corporation

13.5.20. Astellas Pharma Inc.

14. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027 By Region

14.1. Introduction / Key Findings

14.2. Historical Market Size (US$ Mn) By Region

14.2.1.North America

14.2.2.Western Europe

14.2.3.Eastern Europe

14.2.4.Latin America

14.2.5.Asia Pacific Excluding Japan

14.2.6.Japan

14.2.7.Middle East and Africa

14.3. Market Size (US$ Mn) Forecast By Region

14.3.1.North America

14.3.2.Western Europe

14.3.3.Eastern Europe

14.3.4.Latin America

14.3.5.Asia Pacific Excluding Japan

14.3.6.Japan

14.3.7.Middle East and Africa

14.4. Market Attractiveness Analysis By Region

15. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Dosage Form

15.1. Introduction/Key Finding

15.2. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016

15.2.1.Tablets

15.2.2.Capsules

15.2.3.Powders

15.2.4.Others

15.3. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027

15.3.1.Tablets

15.3.2.Capsules

15.3.3.Powders

15.3.4.Others

15.4. Key Trends / Developments

15.5. Drivers and Restraints: Impact Analysis

15.6. Market Attractiveness Analysis By Dosage Form Type

16. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Drug Release Mechanism

16.1.Introduction/Key Finding

16.2. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016

16.2.1.Immediate Release

16.2.2.Extended Release

16.2.2.1.Sustained Release

16.2.2.2.Controlled Release

16.2.3.Others

16.3. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017

16.3.1.Immediate Release

16.3.2.Extended Release

16.3.2.1.Sustained Release

16.3.2.2.Controlled Release

16.3.3.Others

16.4. Key Trends / Developments

16.5. Drivers and Restraints: Impact Analysis

16.6.Market Attractiveness Analysis By Drug Release Mechanism

17. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel

17.1. Introduction/Key Finding

17.2. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016

17.2.1.Hospital Pharmacy

17.2.2.Retail Pharmacy

17.2.3.Drug Stores

17.2.4.Online Pharmacy

17.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027

17.3.1.Hospital Pharmacy

17.3.2.Retail Pharmacy

17.3.3.Drug Stores

17.3.4.Online Pharmacy

17.4. Drivers and Restraints: Impact Analysis

17.5. Market Attractiveness Analysis By Distribution Channel

18. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027

18.1. Market Size and Y-o-Y Growth

18.2. Absolute $ Opportunity

18.3. Value Chain



【レポートのキーワード】

経口医薬製剤

★調査レポート[経口医薬製剤の世界市場] (コード:FUMI709067)販売に関する免責事項を必ずご確認ください。
★調査レポート[経口医薬製剤の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆